[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,192,035
  • Shares Outstanding, K 33,786
  • Annual Sales, $ 55,230 K
  • Annual Income, $ -164,080 K
  • EBIT $ -135 M
  • EBITDA $ -134 M
  • 60-Month Beta 1.24
  • Price/Sales 39.77
  • Price/Cash Flow N/A
  • Price/Book 3.81

Options Overview Details

View History
  • Implied Volatility 66.69% (+2.83%)
  • Historical Volatility 61.61%
  • IV Percentile 11%
  • IV Rank 2.76%
  • IV High 558.45% on 06/05/25
  • IV Low 52.76% on 05/15/26
  • Expected Move (DTE 17) 6.39 (10.13%)
  • Put/Call Vol Ratio 0.95
  • Today's Volume 1,348
  • Volume Avg (30-Day) 1,976
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 35,413
  • Open Int (30-Day) 39,991
  • Expected Range 56.70 to 69.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.05
  • Number of Estimates 7
  • High Estimate $-1.22
  • Low Estimate $-2.74
  • Prior Year $-2.78
  • Growth Rate Est. (year over year) +26.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.76 +0.86%
on 05/27/26
88.10 -28.15%
on 05/04/26
-23.16 (-26.79%)
since 05/01/26
3-Month
62.50 +1.28%
on 03/09/26
109.00 -41.93%
on 04/20/26
-5.68 (-8.23%)
since 02/27/26
52-Week
7.99 +692.24%
on 06/16/25
109.00 -41.93%
on 04/20/26
+52.43 (+482.47%)
since 05/30/25

Most Recent Stories

More News
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

SAN FRANCISCO , May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare...

NKTR : 63.79 (-1.68%)
Nektar Therapeutics Q1 Earnings Call Highlights

Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial...

NKTR : 63.79 (-1.68%)
Nektar: Q1 Earnings Snapshot

Nektar: Q1 Earnings Snapshot

NKTR : 63.79 (-1.68%)
Nektar Therapeutics Reports First Quarter 2026 Financial Results

SAN FRANCISCO , May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.

NKTR : 63.79 (-1.68%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The...

NKTR : 63.79 (-1.68%)
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

NKTR : 63.79 (-1.68%)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR

NEW YORK , May 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).

NKTR : 63.79 (-1.68%)
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NEW YORK , May 4, 2026 /PRNewswire/ -- 

NKTR : 63.79 (-1.68%)
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on...

NKTR : 63.79 (-1.68%)
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

LOS ANGELES , May 4, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations...

NKTR : 63.79 (-1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 68.05
2nd Resistance Point 66.77
1st Resistance Point 65.82
Last Price 63.79
1st Support Level 63.59
2nd Support Level 62.31
3rd Support Level 61.36

See More

52-Week High 109.00
Fibonacci 61.8% 70.41
Last Price 63.79
Fibonacci 50% 58.49
Fibonacci 38.2% 46.58
52-Week Low 7.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.